Urinary Prostate Cancer 3 Test: Toward the Age of Reason?

Vlaeminck-Guillem, Virginie; Ruffion, A.; André, Jean; Devonec, M.; Paparel, P.

doi:10.1016/j.urology.2009.03.046

Cited by 74 publications

(46 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Setting a PCA3 cut-off at 20 vs 35 would have avoided 22.9% vs 38.1% of biopsies but 3 (9.4%) and 9 cases (28%) of cancer with GS of 6 would have been missed. Despite these interesting reports, PCA3 accuracy (cut-off ≥ 35) at repeated biopsy remains contradictory: sensitivity, specificity, PPV and NPV range between 47 to 76.6% (5), 66.6 to 78.6% (6), 39 to 74% (16) and 62.5 to 87% (17), respectively; in fact, only NPV is satisfactory being > 80% in three of the five studies evaluated (5,6,17,18,19).…”

Section: Discussionmentioning

confidence: 99%

PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35?

et al. 2012

View full text Add to dashboard Cite

ARTIcLE INFO _________________________________________________________ ___________________Purpose: To compare PCA3 score cut-off of 35 vs 20 in PCa diagnosis in patients undergoing repeated saturation prostate biopsy (SPBx). Material and Methods: From January 2010 to May 2011, 118 patients (median 62.5 years) with primary negative extended biopsy underwent a transperineal SPBx (median 30 cores) for persistent suspicion of PCa. The indications for repeated biopsy were: persistently high or increasing PSA values; PSA > 10 ng/mL, PSA values between 4.1-10 or 2.6-4 ng/mL with free/total PSA ≤ 25% and ≤ 20%, respectively; moreover, before performing SPBx urinary PCA3 score was evaluated. Results: All patients had negative DRE and median PSA was 8.5 ng/mL (range: 3.7-24 ng/mL). A T1c PCa was found in 32 patients (27.1%): PCA3 score was 59 (median; range: 7-201) in the presence of PCa and 35 (median; in the absence of cancer (p < 0.05). In the presence of ASAP and HGPIN median PCA3 score was 109 (range: 42-253) and 40 (range: 30-140), respectively. Diagnostic accuracy, sensitivity, specificity, PPV and NPV of PCA3 score cut-off of 20 vs 35 in PCa diagnosis were 44.9 vs 50%, 90.6 vs 71.9%, 27.9 vs 41.8%, 31.9 vs 31.5% and 88.9 vs 80%, respectively. ROC analysis demonstrated an AUC for PCA3 ≥ 20 vs ≥ 35 of 0.678 and 0.634, respectively. Conclusions: Our data suggest that PCA3 is more useful as an exclusion tool; moreover, setting a PCA3 cut-off at 20 vs 35, would have avoided 22.9 vs 38.1% of biopsies while missing 9.4% and 28% diagnosis of PCa.

show abstract

Section: Discussionmentioning

confidence: 99%

PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35?

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Recently, in a review (11) of clinical studies with 2048 men undergoing a first or repeat biopsy, the area under curve (AUC) for PCA3 was 0.66-0.87, while the AUC for PSA always scored less. In comparison with PSA, the specificity of PCA3 was better (66-89%), while the sensitivity was less (54-82%).…”

Section: Discussionmentioning

confidence: 99%

“…The association of PCA3 with prostatectomy tumor volume and other clinical/pathological features was assessed by several authors. In most studies PCA3 was significantly correlated with tumor volume, pT stage and Gleason score (GS) (11). Moreover, PCA3 was significantly higher in patients with clinical significant PCa (dominant tumor volume > 0.5 cc and GS ≥ 7) (5).…”

Section: Discussionmentioning

confidence: 99%

“…Three successive generations of the PCA3 test have been presented, leading to a commercially available kit known as the ProgensaTM PCA3 assay (Gen-Probe, San Diego, CA, USA) (11). Fortunately, this novel fast and easy transcription-mediated amplification (TMA)-based test has replaced the older intensive and time-consuming reverse-transcriptase polymerase chain reaction test (5).…”

Section: Pca3 Testmentioning

confidence: 99%

“…Fortunately, this novel fast and easy transcription-mediated amplification (TMA)-based test has replaced the older intensive and time-consuming reverse-transcriptase polymerase chain reaction test (5). The TMA-based PCA3 assay consists of the following steps: i) specific isolation of the RNA of interest by using coated magnetic beds, ii) amplification, and iii) detection and quantification of the isolated RNA (11). Informative rates (percentage of urine samples yielding accurately quantifiable mRNAs for assay) are > 99% and the assays have good reproducibility (12).…”

Section: Pca3 Testmentioning

confidence: 99%

See 2 more Smart Citations

The novel prostate cancer antigen 3 (PCA3) biomarker

et al. 2010

View full text Add to dashboard Cite

PCA3 is a prostate specific, nonprotein coding RNA that is significantly over expressed in prostate cancer, without any correlation to prostatic volume and/or other prostatic diseases (e.g. prostatitis). It can now easily be measured in urine with a novel transcription-mediated amplification based test. Quantification of PCA3 mRNA levels can predict the outcome of prostatic biopsies with a higher specificity rate in comparison to PSA. Several studies have demonstrated that PCA3 can be used as a prognostic marker of prostate cancer, especially in conjunction with other predictive markers. Novel PCA3-based nomograms have already been introduced into clinical practice. PCA3 test may be of valuable help in several PSA quandary situations such as negative prostatic biopsies, concomitant prostatic diseases, and active surveillance. Results from relevant clinical studies, comparative with PSA, are warranted in order to confirm the perspective of PCA3 to substitute PSA.

show abstract

Markers in Prostate Cancer

Cheetham

2014

Prostate Cancer

View full text Add to dashboard Cite

Urinary Prostate Cancer 3 Test: Toward the Age of Reason?

Cited by 74 publications

References 24 publications

PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35?

PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35?

The novel prostate cancer antigen 3 (PCA3) biomarker

Markers in Prostate Cancer

Contact Info

Product

Resources

About